Novartis and Siemens Collaborate to Develop Blood Tests for Multiple Sclerosis
Shots:
- The companies enter in a master agreement to design- develop- and commercialize diagnostic tests for therapies Novartis’ therapeutic pipeline
- The collaboration will initially focus on the development of serum neurofilament light chain (NfL) immunoassay for patients with MS and other neurological diseases
- Siemens will leverage its expertise in the development of clinical diagnostic solutions that can run on Siemens’ global population of ADVIA Centaur and Atellica immunoassay platforms designed for use in hospitals- reference laboratories- and specialty laboratories
Ref: PRNewswire | Image: Novartis
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com